Expired CME Article

Adverse Drug Reactions: Part I

Authors: James M. Wooten, PharmD

Abstract

Pharmacovigilance is the process of identifying, monitoring, and effectively reducing adverse drug reactions. Adverse drug reactions (ADRs) are an important consideration when assessing a patient's health. The proliferation of new pharmaceuticals means that the incidence of ADRs is increasing. The goal for all health care providers must be to minimize the risk of ADRs as much as possible. Steps to achieve this include understanding the pharmacology for all drugs prescribed and proactively assessing and monitoring those patients at greatest risk for developing an ADR. Groups at greatest risk for developing ADRs include the elderly, children, and pregnant patients, as well as others. Pharmacovigilance must effectively be practiced by all health providers in order to avoid ADRs.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Oyez Project, U.S. Supreme Court Media on Potter Stewart. Available at: http://www.oyez.org/justices/potter_stewart/. Accessed February 1, 2010.
 
2. Hohl CM, Robitaille C, Lord V, et al. Emergency physician recognition of adverse drug-related events in elder patients presenting to an emergency department. Acad Emerg Med 2005;12:197–205.
 
3. Farcas A, Bojita M. Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J Gastrointestin Liver Dis 2009;18:353–358.
 
4. Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions. Geneva, Switzerland, World Health Organization, 2002. Available at: http://whqlibdoc.who.int/hq/2002/WHO_EDM_QSM_2002.2.pdf. Accessed January 26, 2010.
 
5. Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. J Pharm Res Health Care 2010;2:127–134.
 
6. Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. World health Organization 2004. pg 1–5. Available at: http://whqlibdoc.who.int/hq/2004/WHO_EDM_2004.8.pdf. Accessed January 26, 2010.
 
7. Ann. Guidance for Industry—Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. 2005. US Food and Drug Administration. Available at:http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf. Accessed March 1, 2010.
 
8. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options [Review]. Am Fam Physician 2003;68:1781–1790.
 
9. Oberg KC. Adverse drug reactions. Am J Pharm Educ. 1999;63:199–204.
 
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–1205.
 
11. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006;26:601–608.
 
12. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009;4:e4439.
 
13. Wooten J. Reporting adverse drug reactions. South Med J 2009;102:345–346.
 
14. Wooten J. Adverse drug reactions. South Med J 2006;99:915.
 
15. Kelly WN. How can I recognize an adverse drug event? Medscape CME Pharmacists 2008. Available at: http://cme.medscape.com/viewarticle/569794?src=mp. Accessed March 2, 2010.
 
16. Pillans PI. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharm 2008;1:695–705.
 
17. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med 2002;55:497–507.
 
18. Woloshin S, Schwartz LM. Bringing the FDA's information to market. Arch Intern Med 2009;169:1985–1987.
 
19. Meadows M. Why drugs get pulled from the market. FDA Consumer Magazine 2002. Available at: http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2002/102_drug.html. Accessed March 2, 2010.
 
20. Greenberger PA. 8. Drug allergy. J Allergy Clin Immunol 2006;117:S464–S470.
 
21. Ann. Guidance for industry: questions and answers regarding adverse event reporting and recordkeeping for dietary supplements as required by the dietary supplement and nonprescription drug consumer protection act. United States Food and Drug Administration 2007. Available at: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/DietarySupplements/ucm171383.htm. Accessed March 2, 2010.
 
22. Tseng DS, Kwong J, Rezvani F, et al. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 2010;123:183.e11–183.e15.